At a glance
ClinicalIndex Comparison RecordN/ACompleted· 103 enrolled
Drug / intervention
Cross-linked hyaluronic acid geldevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Deficiency
In Brief
A clinical study evaluating Cross-linked hyaluronic acid gel for Mid-face Volume Deficiency. Completed, enrolled 103 participants across 1 site.
Detailed Summary
This is a prospective, open-label experience study to be conducted at 6 clinical sites in Australia, with the objective to collect efficacy and safety information for Juvederm® VOLUMA™ when used for volumising the mid-face and cheek area.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMid-face Volume Deficiency
CountriesAustralia
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedDec 2009
Primary CompletionApr 2011
Study CompletionOct 2011
TodayJul 2026
First PostedDec 10, 2009
Enrollment StartJan 1, 2009
Primary CompletionApr 1, 2011
Study CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.6 years ago
Interventions
Cross-linked hyaluronic acid geldevice
Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.